Preoperative Free Ferrous Protoporphyrin and Reactive Oxygen Species Status of Voided Urine Predicts Potential Recurrence Risk in NMIBC

References

• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.010
   PubMed Web of Science ®Google Scholar
• Richters A, Aben K, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904. doi:10.1007/s00345-019-02984-4
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Lobo N, Shariat SF, Guo CC, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020;6(4):653–663. doi:10.1016/j.euf.2019.09.003
   PubMedGoogle Scholar
• Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991. doi:10.1001/jama.2020.17598
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(Suppl 6):4–34. doi:10.1016/j.urology.2005.07.062
   PubMed Web of Science ®Google Scholar
• Soukup V, Čapoun O, Cohen D, et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European association of urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus. 2020;6(3):479–489. doi:10.1016/j.euf.2018.11.005
   PubMedGoogle Scholar
• Ritch CR, Velasquez MC, Kwon D, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020;203(3):505–511. doi:10.1097/JU.0000000000000593
   PubMed Web of Science ®Google Scholar
• van den Bosch S, Alfred WJ. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493–500. doi:10.1016/j.eururo.2011.05.045
   PubMed Web of Science ®Google Scholar
• You M, Li H, Gao Y, et al. Clinical application value of FH/ROS combined test in cervical cancer screening. Hans J Biomed. 2019;9(4):149–153. doi:10.12677/HJBM.2019.94022
   Google Scholar
• Zhao F, Qi N, Shen X, et al. Free ferrous protoporphyrin and reactive oxygen species status of voided urine predicts higher stage in urothelial carcinoma. Cancer Manag Res. 2022;14:615–621. doi:10.2147/CMAR.S352127
   PubMed Web of Science ®Google Scholar
• Karaoglu I, van der Heijden AG, Witjes JA. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol. 2014;32(3):651–659. doi:10.1007/s00345-013-1035-1
   PubMed Web of Science ®Google Scholar
• Yafi FA, Brimo F, Steinberg J, et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33(2):66.e25–31. doi:10.1016/j.urolonc.2014.06.008
   PubMed Web of Science ®Google Scholar
• Chung W, Bondaruk J, Jelinek J, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1483–1491. doi:10.1158/1055-9965.EPI-11-0067
   PubMed Web of Science ®Google Scholar
• Georgopoulos P, Papaioannou M, Markopoulou S, et al. DNA hypermethylation of a panel of genes as an urinary biomarker for bladder cancer diagnosis. Urol J. 2021;19(3):214–220. doi:10.22037/uj.v18i.6743
   PubMed Web of Science ®Google Scholar
• Papaefstathiou E, Papaioannou M, Papaefstathiou E, et al. Do we have enough evidence to propose a urinary biomarker of bladder ischemia? A systematic review and meta-analysis. Low Urin Tract Symptoms. 2022. doi:10.1111/luts.12443
   PubMed Web of Science ®Google Scholar
• Giorgio M, Trinei M, Migliaccio E, et al. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol. 2007;8(9):722–728. doi:10.1038/nrm2240
   PubMed Web of Science ®Google Scholar
• Ryter SW, Kim HP, Hoetzel A, et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal. 2007;9(1):49–89. doi:10.1089/ars.2007.9.49
   PubMed Web of Science ®Google Scholar
• Kostyuk VA, Potapovich AI. Mechanisms of the suppression of free radical overproduction by antioxidants. Front Biosci. 2009;1(1):179–188. doi:10.2741/E17
   Google Scholar
• Buico A, Cassino C, Ravera M, et al. Oxidative stress and total antioxidant capacity in human plasma. Redox Rep. 2009;14(3):125–131. doi:10.1179/135100009X392557
   PubMed Web of Science ®Google Scholar
• Chiabrando D, Vinchi F, Fiorito V, et al. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front Pharmacol. 2014;5:61. doi:10.3389/fphar.2014.00061
   PubMed Web of Science ®Google Scholar
• Lipinski P, Starzyński RR, Styś A, et al. [Heme metabolism as an integral part of iron homeostasis]. Postepy Hig Med Dosw. 2014;68:557–570. Polish. doi:10.5604/17322693.1102284
   Web of Science ®Google Scholar
• Marengo B, Nitti M, Furfaro AL, et al. Redox homeostasis and cellular antioxidant systems: crucial players in cancer growth and therapy. Oxid Med Cell Longev. 2016;2016:6235641. doi:10.1155/2016/6235641
   PubMed Web of Science ®Google Scholar
• Orino K. Functional binding analysis of human fibrinogen as an iron- and heme-binding protein. Biometals. 2013;26(5):789–794. doi:10.1007/s10534-013-9657-8
   PubMed Web of Science ®Google Scholar
• Zhou X, Zuo JH, Wu ZY, et al. Clinical diagnostic value of free body of reduced iron protoporphyrin in uterus epithelial cells on cervical carcinoma and precancerous lesion. Eur Rev Med Pharmacol Sci. 2017;21(9):2145–2149.
   PubMed Web of Science ®Google Scholar